Journal of Alzheimer's Disease 32 (2012) 1–3
IOS Press

Supplementary Data

HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease

Fabio Di Domenico[a,*], Eugenio Barone[b,1], Cesare Mancuso[b], Marzia Perluigi[a], Annalisa Cocciolo[a], Patrizia Mecocci[c], D. Allan Butterfield[d] and Raffaella Coccia[a]
[a]*Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy*
[b]*Institute of Pharmacology, Catholic University School of Medicine, Roma, Italy*
[c]*Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy*
[d]*Department of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA*

Handling Associate Editor: Kenneth Hensley

Accepted 30 May 2012



Supplementary Figure 1. Heme oxygenase-1 (HO-1) protein-bound 4-hydroxynonenal (HNE). No alteration of protein-bound HNE are shown during AD progression.

[1]Current address: Brain Mind Institute, School of Life Sciences Swiss Federal Institute of Technology (EPFL) Station 15, Lausanne, Switzerland.

*Correspondence to: Fabio Di Domenico, Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, P.le Aldo Moro, Rome 5 00185, Italy. Tel.: +39 0649910900; Fax: +39 064440062; E-mail: fabio.didomenico@uniroma1.it.

ISSN 1387-2877/12/$27.50



Supplementary Figure 2. Correlation results of HO-1/BVR-A alteration found in our study and IADL values.

Supplementary Table 1
Detailed information of all patients enrolled for the study

Subject[#]	Gender	Age	MMSE	ADL	IADL	GDS	CDR	HIS	CHOL	BSE	CRP
pAD 1	F	80	18/30	5/6	2/8	7/15	1	2	235	15	0.25
pAD 2	F	85	13/30	6/6	3/8	4/15	1	0	273	35	0.3
pAD 4	F	85	9/30	3/6	0/8		2	3	243	41	1.2
pAD 5	F	83	26/30	4/6	2/8	3/15	1	2	203	50	0.8
pAD 6	F	79	11/30	5/6	3/8	8/15	1	2	155	25	0.4
pAD 7	M	85	21/30	6/6	3/8	0/15	1	0	181	15	0.25
pAD 8	F	85	/	/	/	/	/	/	285	39	0.2
pAD 9	F	82	23/30	5/6	6/8	3/15	1	1	179	14	0.2
pAD 10	F	79	24/30	5/6	4/8	5/15	1	3	204	9	0.1
pAD 11	F	83	18/30	6/6	5/8	7/15	1	/	227	17	0.1
pAD 12	M	88	22/30	6/6	0/8	5/15	1	4	219	34	1.3
pAD 3	M	73	15/30	4/6	4/8	5/15	1	4	219	/	/
pAD AVG	**9 F, 3 M**	**82.2**	**18.2/30**	**4.9/6**	**2.9/8**	**4.7/15**	**1**	**2.1**	**218**	**26.7**	**0.5**
MCI 11	M	75	18/30	5/6	3/8	12/15	0.5	4	176	31	1.5
MCI 1	F	84	24/30	5/6	7/8	2/15	0.5	1	243	22	0.3
MCI 3	M	87	27/30	6/6	5/8	1/15	0.5	0	152	31	1.3
MCI 4	M	71	24/30	5/6	3/8	0/15	0.5	2	167	25	3.1
MCI 5	F	71	28/30	5/6	8/8	0/15	0.5	2	223	29	0.4
MCI 6	M	80	26/30	6/6	3/8	5/15	0.5	2	120	19	0.5
MCI 7	M	80	24/30	2/6	1/8	2/15	0.5	4	94	35	0.1
MCI 9	M	75	29/30	6/6	8/8	0/15	0.5	2	241	5	0.1
MCI 10	M	83	24/30	5/6	5/8	5/15	0.5	1	205	13	0.1
MCI 11	M	81	23/30	5/6	7/8	9/15	0.5	1	268	/	/
MCI 12	F	86	22/30	2/6	3/8	10/15	0.5	2	237	/	/
MCI 2	F	78	23/30	6/6	4/8	13/15	0.5	2	206	/	/
MCI AVG	**4 F, 8 M**	**79.2**	**24.3/30**	**4.8/6**	**4.7/8**	**4.9/15**	**0.5**	**1.9**	**194.3**	**23.3**	**0.80**
CTR 1	M	66	29/30	5/6	5/8	12/15	0	1	193	39	0.1
CTR 4	M	75	30/30	6/6	8/8	0/15	0	2	90	11	0.4
CTR 5	M	68	30/30	6/6	4/8	6/15	0	2	259	6	0.1
CTR 6	F	80	25/30	5/6	5/8	6/15	0	/	210	28	0.5
CTR 8	F	89	25/30	6/6	7/8	10/15	0	3	245	15	0.1
CTR 10	F	83	26/30	6/6	7/8	3/15	0	2	183	15	0.1
CTR 2	F	81	28/30	6/6	8/8	5/15	0	2	/	15	0.1
CTR 7	F	85	30/30	5/6	6/8	11/15	0	1	/	15	0.1
CTR 9	M	84	30/30	6/6	8/8	0/15	0	1	140	29	0.2
CTR 11	M	88	27/30	5/6	7/8	9/15	0	1	209	/	/
CTR 12	M	75	30/30	5/6	5/8	14/15	0	1	201	/	/
CTR 3	F	84	29/30	5/6	7/8	6/15	0	2	184	/	/
CTR AVG	**6 F, 6 M**	**79.8**	**28.2/30**	**5.5/6**	**6.5/8**	**5.9/15**	**0**	**1.6**	**191.4**	**19.2**	**0.16**

ADL, activities of daily living; BSE, erythrocytes sedimentation; CDR, clinical dementia rating; CHOL, cholesterol levels; CRP, C-reactive protein; GDS, geriatric depression scale, HIS, Hachinski ischemic score; IADL, instrumental activities of daily living; MCI, mild cognitive impairment; pAD, probable Alzheimer's disease.